Business Wire

NY-OPENTRONS

10.9.2019 13:02:06 CEST | Business Wire | Press release

Share
Opentrons Launches The World’s Most Fully Affordable Thermocycler

Opentrons, the company making lab robotics accessible, launched the most affordable fully automated thermocycler ever, bringing end-to-end PCR based workflow automation to biologists everywhere.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005100/en/

Today many products on the market allow biologists to automate key parts of their workflows, but most lab robots still require human intervention between steps. This breaks workflows into smaller automated chunks, requiring scientists to manipulate their samples themselves -- and not really freeing biologists of repetitive and error-prone labwork. With the launch of their on-deck, automated thermocycler, Opentrons is relieving one of the main pain points preventing biologists from having fully automated, “walk away” lab solutions.

The Opentrons Thermocycler, priced at $4,000, is designed to fit directly on the deck of the OT-2 pipetting robot, and is as fast and accurate as machines 10x the price. This unlocks end-to-end automation of important protocols like NGS Library Prep, PCR genotyping, DNA assembly, PCR mutagenesis, and many more.

“Before thermocyclers, biologists ran PCR by moving tubes from water bath to water bath by hand,” said Will Canine, Co-Founder and Chief Product Officer of Opentrons. “Thermocyclers automated that tedious process, and we’re now taking it one step further to also automate the pipetting steps before and after thermocycling -- all at a revolutionary price point accessible to biologists worldwide.”

Biologists can download protocols for important experiments like NGS Library Prep, genotyping PCR, and DNA assembly with the click of a button, or even create their own from scratch without needing programming skills or a technical team. This combination of affordability, ease-of-use, and powerful automation is changing the way many biologists do their day-to-day work.

About Opentrons

Opentrons is making automation accessible for any lab, starting with affordable pipetting robots for biologists. With its easy-to-use hardware and an open software platform, Opentrons automates manual lab work and empowers collaborative research for life scientists. Opentrons has helped over 1,000 labs in 45 countries save time, money and lab costs -- including 47 of the top 50 academic universities in the world such as MIT, Oxford, and Stanford, and 9 of the top 10 pharmaceutical companies such as GSK, Merck, and Novartis. To learn more, visit www.opentrons.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release

Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion

Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 15:35:00 CEST | Press release

Accomplished AI and technology executive to lead IAS's next phase of innovation and growth; Lisa Utzschneider to serve as Special Advisor to the Board through year-end Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 15:00:00 CEST | Press release

Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in

SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 15:00:00 CEST | Press release

Building on live tokenized fund issuance and distribution capabilities, SS&C extends its innovation roadmap to support the next stage of digital investment markets SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactio

Gurobi Launches Intelligence Hub to Deliver AI-Guided Workflows Across the Optimization Lifecycle7.7.2026 15:00:00 CEST | Press release

The Hub introduces specialized AI agents designed to make optimization more accessible for all users. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of the Gurobi Intelligence Hub, the new home for Gurobi’s AI-powered optimization agents. The Intelligence Hub is designed to help users build, understand, troubleshoot, and interact with optimization models more effectively. Together, the Hub’s specialized agents leverage generative AI to guide users through workflows across the optimization lifecycle, creating new opportunities to make optimization more accessible, intuitive, and valuable for a broader range of users.The Modeler combines guided workflows with Gurobi’s optimization expertise to help users move from business problem to production-quality optimization model. Through an iterative process that helps refine requirements, validate assumptions, and develop acceptance tests, the Modeler gives users confidence that their model

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye